title: Risk of Tractional Retinal Detachment Following Intravitreal Bevacizumab Along with Subretinal Fluid Drainage and Cryotherapy for Stage 3B Coats' Disease.
abstract: OBJECTIVE
  To review the surgical outcomes of intravitreal bevacizumab (IVB) along with subretinal fluid drainage with cryotherapy in patients with stage 3B Coats' disease.
  
  
  METHODS
  A retrospective study of seven cases of stage 3B Coats' disease, who underwent subretinal fluid drainage with cryopexy, from May 2011 to March 2014. Five eyes received additional IVB at the end of surgery. Green laser therapy was performed on telangiectatic vessels postoperatively.
  
  
  RESULTS
  The mean age was 34 months (range, 10-84 months). Mean follow-up was 19 months. Six patients (85.7%) had an attached retina at final follow-up. Three out of four patients (75%) that received IVB developed tractional retinal detachments (TRDs). Two eyes that did not receive bevacizumab did not develop any traction. None progressed to neovascular glaucoma or phthisis bulbi.
  
  
  CONCLUSIONS
  Simultaneous injection of bevacizumab along with subretinal drainage and cryotherapy for advanced Coats' disease could not avoid TRD.
authors.affiliation: Department of Pediatric Retina and Ocular Oncology, Aravind Eye Hospital and Postgraduate Institute of Ophthalmology, Coimbatore, Tamil Nadu, India.
authors.forename: Vishalakshi
authors.initials: V
authors.lastname: Bhat
authors.affiliation: Department of Pediatric Retina and Ocular Oncology, Aravind Eye Hospital and Postgraduate Institute of Ophthalmology, Coimbatore, Tamil Nadu, India.
authors.forename: Palmeera
authors.initials: P
authors.lastname: D'Souza
authors.affiliation: Department of Pediatric Retina and Ocular Oncology, Aravind Eye Hospital and Postgraduate Institute of Ophthalmology, Coimbatore, Tamil Nadu, India.
authors.forename: Parag K
authors.initials: PK
authors.lastname: Shah
authors.affiliation: Department of Pediatric Retina and Ocular Oncology, Aravind Eye Hospital and Postgraduate Institute of Ophthalmology, Coimbatore, Tamil Nadu, India.
authors.forename: V
authors.initials: V
authors.lastname: Narendran
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000068258:Bevacizumab / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D017679:Cryotherapy; D004322:Drainage; D005260:Female; D006801:Humans; D007223:Infant; D058449:Intravitreal Injections / Q000009:adverse effects; D008297:Male; D012163:Retinal Detachment / Q000453:epidemiology* / Q000209:etiology; D058456:Retinal Telangiectasis / Q000145:classification / Q000628:therapy*; D012189:Retrospective Studies; D012307:Risk Factors; D058471:Subretinal Fluid; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab
keywords: Advanced Coats’ Disease; Bevacizumab; Tractional Retinal Detachment